Bing

SEARCH HISTORY

The FDA has sent the biotech -- and its stock price -- on a roller coaster tied to whether ... The meeting may be combined with one for BioMarin Pharmaceuticals' (NASDAQ: BMRN) competing Duchenne muscular dystrophy drug, drisapersen. BioMarin …
Investopedia · 5/20/2015
BioMarin Pharmaceutical (BMRN) saw its price spike on above-average volume today, as 2.8 million shares, which is two times the stock's average daily volume, traded hands. The stock price reached $42.32, a 3.8% increase. Over the last three months ...
Fox Business · 7/9/2012
Vosoritide has Orphan designation in both the United States and Europe. BMRN closed Wednesday's trading 2.06% higher at $123.60. In after-hours, the stock was up 6.43% at $131.55. CorMedix Inc. (CRMD) has received positive feedback from the FDA …
Realtime Business News · 6/18/2015
U.S. stock futures advanced today as investors welcomed the Federal ... BioMarin Pharmaceutical (NASDAQ:BMRN) climbed 6.4 percent after the Novato, California-based company said its experimental drug for achondroplasia, or dwarfism, helped children …
Proactiveinvestors · 6/18/2015
“collars”; Biomarin (BMRN) has Ph. 2 in BMN111 coming before the end of the month; in my opinion it will be a significant catalyst for the stock price either way; an even bigger – almost binary event (for the stock, NOT for the company) arrives in ...
seeitmarket.com · 6/10/2015
Hard times can make for hard feelings between former drug development partners, which seems to be what’s happening between Novato, CA-based BioMarin (NASDAQ: BMRN) and San Diego’s ailing La Jolla Pharmaceutical (NASDAQ: LJPC). Once the …
Xconomy · 6/23/2009
BMRN) today announced that on April 15, 2015, the compensation committee of BioMarin's board of directors approved the grant to 58 newly hired employees of 48,320 restricted share units in the aggregate and stock options to purchase 1,500 shares of …
Virtual-Strategy Magazine · 4/21/2015
BioMarin Pharmaceutical, Inc.(NASDAQ:BMRN) is expected to present preliminary results from on-going BMN-701 Phase I/II trial in Pompe disease, which a progressive degenerative disease of the heart muscle, diaphragm and skeletal muscle. Feb.28 – …
istock Analyst · 2/5/2013
... BMRN) fits the same description. A blog post that, by its own admission, "might be codswallop," reported that the former is considering buying the latter. And those three facts combined to send the shares of BioMarin, far from a penny stock, up as ...
Fierce Biotech · 3/27/2015
Is BioMarin Pharmaceutical Inc. a good stock to buy now? Shares of the company are surging today after the pharmaceutical firm revealed positive results of its Phase 2 study on BMN 111 , a drug that aims to treat achondroplasia, the most frequent form of ...
topix.com · 7/9/2015